A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Chronic Lymphocytic Leukemia
Related studies linked through entity extraction aliases.
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE3
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
- Status
- WITHDRAWN
- Phase
- PHASE1
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
- Status
- COMPLETED
- Phase
- PHASE2
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program
- Status
- COMPLETED
- Phase
- N/A
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
- Status
- COMPLETED
- Phase
- PHASE2
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
- Status
- COMPLETED
- Phase
- NA
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
- Status
- COMPLETED
- Phase
- PHASE1
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
- Status
- UNKNOWN
- Phase
- PHASE2
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia
- Status
- COMPLETED
- Phase
- N/A
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
- Status
- COMPLETED
- Phase
- PHASE2
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3